These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 32511395)
41. Effect of the povidone iodine, hypertonic alkaline solution and saline nasal lavage on nasopharyngeal viral load in COVID-19. Batioglu-Karaaltin A; Yigit O; Cakan D; Akgul O; Yigit E; Yilmaz YZ; Cakir KB; Ciftci G; Boyoğlu NS; Cagliyan A; Can E; Dikme O; Hacioglu Y; Balkan II; Enver O; Ozdogan HA Clin Otolaryngol; 2023 Jul; 48(4):623-629. PubMed ID: 36973223 [TBL] [Abstract][Full Text] [Related]
42. Disinfection methods against SARS-CoV-2: a systematic review. Viana Martins CP; Xavier CSF; Cobrado L J Hosp Infect; 2022 Jan; 119():84-117. PubMed ID: 34673114 [TBL] [Abstract][Full Text] [Related]
43. Effects of povidone-iodine composite on the elimination of bacterial biofilm. Jeronimo LP; Choi MR; Yeon SH; Park SK; Yoon YH; Choi SH; Kim HJ; Jang IT; Park JK; Rha KS; Kim YM Int Forum Allergy Rhinol; 2020 Jul; 10(7):884-892. PubMed ID: 32479710 [TBL] [Abstract][Full Text] [Related]
50. In vitro studies evaluating the efficacy of mouth rinses on Sars-Cov-2: A systematic review. Tadakamadla J; Boccalari E; Rathore V; Dolci C; Tartaglia GM; Tadakamadla SK J Infect Public Health; 2021 Sep; 14(9):1179-1185. PubMed ID: 34399189 [TBL] [Abstract][Full Text] [Related]
51. Outbreak of highly pathogenic avian influenza in Japan and anti-influenza virus activity of povidone-iodine products. Ito H; Ito T; Hikida M; Yashiro J; Otsuka A; Kida H; Otsuki K Dermatology; 2006; 212 Suppl 1():115-8. PubMed ID: 16490988 [TBL] [Abstract][Full Text] [Related]
52. Antiviral effect of mouthwashes against SARS-COV-2: A systematic review. Mezarina Mendoza JPI; Trelles Ubillús BP; Salcedo Bolívar GT; Castañeda Palacios RDP; Herrera Lopez PSG; Padilla Rodríguez DA; Uchima Koecklin KH Saudi Dent J; 2022 Mar; 34(3):167-193. PubMed ID: 35125835 [TBL] [Abstract][Full Text] [Related]
53. A prospective, randomized, open-label trial of early versus late povidone-iodine gargling in patients with COVID-19. Matsuyama A; Okura H; Hashimoto S; Tanaka T Sci Rep; 2022 Nov; 12(1):20449. PubMed ID: 36443363 [TBL] [Abstract][Full Text] [Related]
54. Povidone-iodine solution as SARS-CoV-2 prophylaxis for procedures of the upper aerodigestive tract a theoretical framework. Naqvi SHS; Citardi MJ; Cattano D; Ostrosky-Zeichner L; Knackstedt MI; Karni RJ J Otolaryngol Head Neck Surg; 2020 Oct; 49(1):77. PubMed ID: 33109269 [TBL] [Abstract][Full Text] [Related]
55. Inactivation of SARS-CoV-2 and HCoV-229E in vitro by ColdZyme® a medical device mouth spray against the common cold. Gudmundsdottir Á; Scheving R; Lindberg F; Stefansson B J Med Virol; 2021 Mar; 93(3):1792-1795. PubMed ID: 32975843 [TBL] [Abstract][Full Text] [Related]
56. Oral antiseptics against coronavirus: in-vitro and clinical evidence. Mateos-Moreno MV; Mira A; Ausina-Márquez V; Ferrer MD J Hosp Infect; 2021 Jul; 113():30-43. PubMed ID: 33865974 [TBL] [Abstract][Full Text] [Related]
57. Nasal disinfection for the prevention and control of COVID-19: A scoping review on potential chemo-preventive agents. Cegolon L; Javanbakht M; Mastrangelo G Int J Hyg Environ Health; 2020 Sep; 230():113605. PubMed ID: 32898838 [TBL] [Abstract][Full Text] [Related]